AZD5363 in combination with fulvestrant in AKT1-mutant ER-positive metastatic breast cancer

被引：0
|
作者：
Smyth, Lillian M.
Oliveira, Mafalda
Ciruelos, Eva
Tamura, Kenji
El-Khoueiry, Anthony
Mita, Alain
You, Benoit
Renouf, Daniel J.
Sablin, Marie-Paule
Lluch, Ana
Mayer, Ingrid A.
Bando, Hideaki
Yamashita, Hiroko
Ambrose, Helen
de Bruin, Elza
Carr, T. Hedley
Corcoran, Claire
Foxley, Andrew
Lindemann, Justin P. O.
Maudsley, Rhiannon
Pass, Martin
Rutkowski, Andrzej
Schiavon, Gaia
Banerji, Udai
Scaltriti, Maurizio
Taylor, Barry S.
Chandarlapaty, Sarat
Baselga, Jose
Hyman, David M.
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
[3] Hosp Univ 12 Octubre, Madrid, Spain
[4] Natl Canc Ctr, Tokyo, Japan
[5] Univ Southern Calif, Los Angeles, CA USA
[6] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[7] Univ Lyon 1, Inst Cancerol, Hosp Civils Lyon, CITOHL, Lyon, France
[8] British Columbia Canc Agcy, Vancouver, BC, Canada
[9] Inst Curie, Paris, France
[10] Inst Curie, St Cloud, France
[11] Hosp Clin Univ, Valencia, Spain
[12] INCLIVA Hlth Res Inst, Valencia, Spain
[13] Univ Valencia, Valencia, Spain
[14] CIBERONC ISCIII, Valencia, Spain
[15] Vanderbilt Breast Ctr, Nashville, TN USA
[16] Hosp East, Natl Canc Ctr, Chiba, Japan
[17] Hokkaido Univ Hosp, Sapporo, Hokkaido, Japan
[18] AstraZeneca, Cambridge, England
[19] Inst Canc Res, London, England
[20] Royal Marsden NHS Fdn Trust, London, England
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-21-32
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Genome-wide CRISPR screens identify combination strategies for Capivasertib (AZD5363; AKT) and AZD8186 (PI3K13/6) in PTENnull breast cancer
    Dunn, Shanade
    Yu, Jason
    Gris-Oliver, Albert
    Pilling, James
    Hoperoft, Philip
    Yelland, Urs
    Cureton, Natalie
    Staniszewsla, Anna
    Au, Yan Zi
    Ong, Swee Hoe
    Isherwood, Beverley
    Serra, Violeta
    Barry, Simon
    Davies, Barry R.
    Lynch, James T.
    Yusa, Kosuke
    CANCER RESEARCH, 2019, 79 (13)
  • [22] A phase I study evaluating AZD2014 in combination with fulvestrant in patients with ER plus advanced metastatic breast cancer
    Burris, Howard, III
    LoRusso, Patricia
    Gluck, W. Larry
    Jones, Suzanne
    Kittaneh, Muaiad
    Hamilton, Erika
    Green, Stephen
    Burke, Wendy
    Strickland, Donald
    Oelmann, Elisabeth
    Patel, Manish
    CANCER RESEARCH, 2015, 75
  • [23] ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer
    Crabb, Simon J.
    Birtle, Alison J.
    Martin, Karen
    Downs, Nichola
    Ratcliffe, Ian
    Maishman, Tom
    Ellis, Mary
    Griffiths, Gareth
    Thompson, Stuart
    Ksiazek, Lidia
    Khoo, Vincent
    Jones, Robert J.
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (05) : 599 - 607
  • [24] Mathematical modeling of ER-positive breast cancer treatment with AZD9496 and palbociclib
    Wei, Hsiu-Chuan
    AIMS MATHEMATICS, 2020, 5 (04): : 3446 - 3455
  • [25] Phase I expansion of olaparib (PARP inhibitor) and AZD5363 (AKT inhibitor) in recurrent ovarian, endometrial and triple negative breast cancer
    Westin, S.
    Litton, J.
    Williams, R.
    Soliman, P.
    Frumovitz, M.
    Schmeler, K.
    Jazaeri, A.
    Sood, A.
    Lu, K.
    Moulder, S.
    Murthy, R.
    Rodriguez, A.
    Samuel, C.
    Engerman, L.
    Cyriac, A.
    Rugman, P.
    Lindemann, J.
    McMurtry, E.
    Mills, G.
    Coleman, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [26] A phase II, double blind, randomised, placebo-controlled study of the AKT Inhibitor AZD5363 in combination with paclitaxel in triple-negative advanced or metastatic breast cancer (TNBC) (NCT02423603)
    Schmid, P.
    Wheatley, D.
    Baird, R.
    Chan, S.
    Abraham, J.
    Tutt, A.
    Kristeleit, H.
    Patel, G.
    Bathakur, U.
    Bishop, J.
    Harper-Wynne, C.
    Sims, E.
    Copson, E.
    Perren, T.
    Stein, R.
    Poole, C.
    Cartwright, H.
    Sarker, S-J
    Mousa, K.
    Turner, N.
    CANCER RESEARCH, 2016, 76
  • [27] ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer
    Simon J. Crabb
    Alison J. Birtle
    Karen Martin
    Nichola Downs
    Ian Ratcliffe
    Tom Maishman
    Mary Ellis
    Gareth Griffiths
    Stuart Thompson
    Lidia Ksiazek
    Vincent Khoo
    Robert J. Jones
    Investigational New Drugs, 2017, 35 : 599 - 607
  • [28] Is fulvestrant more effective than tamoxifen for treating ER-positive breast cancer in postmenopausal women?
    Raina, Vinod
    NATURE CLINICAL PRACTICE ONCOLOGY, 2004, 1 (01): : 20 - 21
  • [29] Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer
    D A Cameron
    D R Camidge
    J Oyee
    M Hirsch
    British Journal of Cancer, 2008, 99 : 1984 - 1990
  • [30] Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer
    Cameron, D. A.
    Camidge, D. R.
    Oyee, J.
    Hirsch, M.
    BRITISH JOURNAL OF CANCER, 2008, 99 (12) : 1984 - 1990
12345